Contrafect Corp (CFRX)

[ClayTrader]

* * $CFRX Video Chart 12-13-2019 * *

Link to Video - click here to watch the technical chart video

[420man]

Took a little profit, but holding for higher ground next week.

[crudeoil24]

ContraFect Corp (NASDAQ: CFRX) said it has commenced an underwritten public offering of shares of its common stock. The company also entered into a stock purchase agreement with Pfizer Inc. (NYSE: PFE), under which the latter has agreed to buy up to $3 million worth of ContraFect shares in a separate private placement at a price equal to the price per share of the proposed common stock offering.

[crudeoil24]

Pfizer is the big engine running the CFRX train!

[crudeoil24]

PFIZER now huge shareholder!

[420man]

Grabbed some...but I'm now out of powder...spread out on many plays. GL

[ClayTrader]

* * $CFRX Video Chart 12-10-2019 * *

Link to Video - click here to watch the technical chart video

[dough_maker]

Any insights on this stock?

[locksflooring]

Here comes all the shorters!

[ClayTrader]

* * $CFRX Video Chart 06-06-2019 * *

Link to Video - click here to watch the technical chart video

[DD]

what happened, ALL-IN

[dmsrz8]

Ugh

[ALL-IN888]

Explosive Chart pattern exactly the same as PRPO from .25 Better load this cheapees while still under the .72 threshold!!! $$$$

[ALL-IN888]

IN @ .68 Lets Explode it above 1.00+ $$$$ BOOM!!!

[ClayTrader]

* * $CFRX Video Chart 04-10-2019 * *

Link to Video - click here to watch the technical chart video

[Awl416]

Don’t blink

[ClayTrader]

* * $CFRX Video Chart 04-09-2019 * *

Link to Video - click here to watch the technical chart video

[naturalborninvestor]

Here we go. $1 target.

[Makk1]

A little patience here and this Will make you money coming weeks.

[Golden Cross]

$CFRX daily chart: MACD had a bullish cross. Looking good

[StockMonster100]

Locked and loaded here peeps.

This stock has an interesting setup. We break .51, then we break .62....from .62 there is a gap fill to 1.73


$$$ BULLISH $$$

[ClayTrader]

* * $CFRX Video Chart 04-04-2019 * *

Link to Video - click here to watch the technical chart video

[Makk1]

Blue skies $$$

[Makk1]

Key break 0.5 about to happen, when this barrier goes down this goes to SPACE.

[davidmicrocap]

I am long on this one since the big drop.
I am postulating if the drop is related to the absence of synergistic effect on MSSA. Of course the trial design at this scale was not for proving efficacy, but it did show some light on the potential effect of CF-301.
Second, the MRSA proportion in Phase II is about 35-40%, it is suspicious if this composition can be sustained in Phase III, although management said this range of MRSA is expected. Since CF-301 is highly effective in MRSA but not in MSSA when used with SoC. The composition of the study population greatly affects the overall efficacy. In other words, if Phase III does not have MRSA portion like this time, then likely we are seeing reduced overall efficacy.
For the left-sided endocarditis, I think it doesn't impose much pressure on stock price. I think from the very beginning, there is limited hope on left-sided endocarditis since it is really difficult to treat with medication. Daptomycin was also approved for bacteremia and right-sided endocarditis around 13 years ago.
However, overall speaking, I think CF-301 likely to show effect on MRSA cases and maybe some effect on MSSA (if left-sided endocarditis is excluded, likely we may see somer effect in Phase III). Therefore, I still think CFRX is a good risk/reward candidate at this share price.

[aristotelisonassis]

long

[ClayTrader]

* * $CFRX Video Chart 03-20-2019 * *

Link to Video - click here to watch the technical chart video

[naturalborninvestor]

more likely 0.50's tomorrow

[Blutribe]

I am buying today seems a good price and value given the recent pullback and news...


YONKERS, N.Y., Jan. 17, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has awarded the Company $2.3 million in additional funding over the course of the next two years. The Company will use the grant for the development of lysin therapeutics to treat serious, potentially life-threatening invasive infections caused by antibiotic-resistant Pseudomonas aeruginosa (P. aeruginosa), a virulent Gram-negative pathogen. This is an increase to the original CARB-X option amount of $1.0 million, part of the Company’s grant from CARB-X in March of 2017.

“We are pleased to have been awarded this additional funding from CARB-X. This follows our recent announcement of positive topline data from the Phase 2 trial of our lead lysin candidate exebacase, or CF-301, for the treatment of Staph aureus bacteremia, including endocarditis, which establishes clinical proof of concept for lysins as therapeutic agents. P. aeruginosa is a major cause of morbidity and mortality, often related to hospital acquired pneumonia, and is a major medical challenge, particularly for patients with cystic fibrosis. We look forward to advancing this program into the clinic as rapidly as possible,” said Cara Casino, M.D., Executive Vice President of Research & Development and Chief Medical Officer of ContraFect.

“We view this additional funding from CARB-X as continued validation of our novel lysin platform, which underscores the opportunity to combat highly resistant Gram-negative pathogens, considered to be the greatest threats to global health by both the CDC and WHO, with our proprietary lysin candidates.” said Steven C. Gilman, Ph.D., Chairman and Chief Executive Officer of ContraFect.

About CARB-X:

CARB-X is the world's largest public-private partnership devoted to antibacterial preclinical R&D. Funded by BARDA, Wellcome Trust, and NIAID, it will spend $450 million from 2017-2021 to support innovative products moving towards human clinical trials. CARB-X focuses on high priority drug-resistant bacteria, especially Gram-negative organisms. CARB-X is a charitable global public-private partnership led by Boston University School of Law. Other partners include the Broad Institute of Harvard and MIT, MassBio, the California Life Sciences Institute and RTI International. For more information, please visit www.carb-x.org and follow them on Twitter @CARB-X.

[umiak]

.30? Who knows? Bears were right on this 1

[aristotelisonassis]

Long!

[umiak]

Picked some up.

[gblxwhale]

Yes I follow it and am a current bag holder from $2.20.
This is a fantastic entry point!
I am still trying to figure out flights down so much when the data they released was actually really good.

[Snakes531]

Why is this dog down so much in the last week

[Snakes531]

Anybody following in stock? Seems like a good entry point but I don’t know why it dropped from $2 to .60

[PennyStock Alert]

We will be well above that very soon

[willlbone]

Bought some at 58 cents.

[PennyStock Alert]

8% gain today :)

[PennyStock Alert]

Large upside here

[PennyStock Alert]

Should see gap up to .75 in pre market.

[PennyStock Alert]

Low volume

[willlbone]

Dead cat bounce.

[Chunky Salsa]

Waiting for consolidation to jump in

[420man]

May bounce around some, but I think it's going to slowly bleed down and then they announce an offering in the .30's. This will take months to recover unless they come out with a stellar 3rd phase test in about 6-8 weeks.

Not to mention that they will very likely get their deficiency notice during that time as well.

Looking for an RSI in the teens for a few weeks before a possible strong bounce play. Jmo

http://schrts.co/G8s1EN

[RLBTrader]

Should see gap up to .75 in pre market.

[willlbone]

50 cent tomorrow.

[420man]

Only thing I could find that makes sense is this article.... https://seekingalpha.com/news/3421090-contrafect-37-percent-mid-stage-exebacase-data

Plus they filed for $100 Shares to be sold from time to time when they see fit.

I sold for tiny profit this morning because I had a strong feeling it would do exactly what it did today.

[willlbone]

Sell the news.
Costs money to run Phase 3 trials.

[gblxwhale]

Really shitty. Thanks for asking. #bagholding

[Disquisition]

BWAHAHAHAHAHAHAH how are your 1.14s looking at .65?